ClinicalTrials.gg
CompletedNCT04340193CheckMate 74WUpdated Nov 26, 2024Results posted

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

A Phase 3 interventional study of nivolumab and ipilimumab in Cancer, Hepatocellular, sponsored by Bristol-Myers Squibb. Completed at 107 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing nivolumab in Liver Neoplasms — 2 open to participants now, 4 under way, 1 of them phase 3. Nivolumab · Liver Neoplasms.

Enrollment
7th of 15
26 · median 22
Started
2020
with 2 others
Phase 3
2 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
4 of 15
Bristol-Myers Squibb

Among the 15 studies testing nivolumab in Liver Neoplasms, this one is the 7th largest by enrollment, is one of 3 that started in 2020, is one of 2 in phase 3, and was the 8th registered.

Liver Neoplasms

1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

2 of the 15 studies testing nivolumab in Liver Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing nivolumab in Liver Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.

03

Conditions studied

  • Cancer, Hepatocellular

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has intermediate-stage hepatocellular carcinoma (HCC) whose tumor characteristics exceed the Beyond Milan and Up-to-7 (BMU7) criteria and is eligible for trans-arterial ChemoEmbolization (TACE)
  • Participant has no extrahepatic spreading (EHS), no regional lymph node involvement, no main, left main, or right main portal vein thrombosis, and no macrovascular invasion (MVI)
  • (ECOG) performance status (PS) 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Prior liver transplant or participants who are on the waiting list for liver transplantation
  • Active, known, or suspected disease

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Nivolumab + Ipilimumab + TACE

    TACE (Trans-arterial ChemoEmbolization)

    Drug: nivolumab · Drug: ipilimumab · Procedure: TACE

  • Experimental
    Nivolumab + TACE

    Drug: nivolumab · Procedure: TACE

  • Active comparator
    TACE

    Procedure: TACE

Interventions

  • Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • Specified dose on specified days

    Also known as: Yervoy

  • ProcedureTACE

    TACE (Trans-arterial ChemoEmbolization)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose that results in death, Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) or requires inpatient hospitalization or causes prolongation of existing hospitalization, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event.

    Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  3. Number of Participants Who Died

    Number of participants who died due to any cause are summarized.

    Time frame: From first dose and 100 days after last dose of study therapy (up to approximately 27 months)

  4. Number of Participants With Adverse Events Leading to Study Drug Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  5. Number of Participants With Worst Grade (Grade 3/4) Laboratory Results

    Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Grade 3 =Severe, Grade 4 = Life-threatening). Highest grade measured for hemoglobin and albumin was Grade 3.

    Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  6. Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

    Blood samples were collected for specific thyroid test.

    Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

  7. Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests

    Blood samples were collected for specific liver tests.

    Time frame: From first dose and 30 days after last dose of study therapy (up to approximately 25 months)

07

Results

Posted Nov 26, 2024

Participant flow

Participant flow — Overall Study
MilestoneNIVO+IPI+TACENIVO+TACETACE
Started998
Completed644
Not completed354
Withdrew: Other reason001
Withdrew: Disease recurrence010
Withdrew: Study drug toxicity100
Withdrew: Disease progression123
Withdrew: Administrative reasons by sponsor010
Withdrew: Adverse event110

Outcome measures

PrimaryNumber of Participants With Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsNIVO+IPI+TACENIVO+TACETACE
Number of Participants With Adverse Events998
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose that results in death, Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) or requires inpatient hospitalization or causes prolongation of existing hospitalization, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event.

Time frame:
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsNIVO+IPI+TACENIVO+TACETACE
Number of Participants With Serious Adverse Events (SAEs)762
PrimaryNumber of Participants Who Died

Number of participants who died due to any cause are summarized.

Time frame:
From first dose and 100 days after last dose of study therapy (up to approximately 27 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsNIVO+IPI+TACENIVO+TACETACE
Number of Participants Who Died220
PrimaryNumber of Participants With Adverse Events Leading to Study Drug Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Study Drug Discontinuation
ParticipantsNIVO+IPI+TACENIVO+TACETACE
Number of Participants With Adverse Events Leading to Study Drug Discontinuation311
PrimaryNumber of Participants With Worst Grade (Grade 3/4) Laboratory Results

Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Grade 3 =Severe, Grade 4 = Life-threatening). Highest grade measured for hemoglobin and albumin was Grade 3.

Time frame:
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Worst Grade (Grade 3/4) Laboratory Results
ParticipantsNIVO+IPI+TACENIVO+TACETACE
Hemoglobin (Grade 3)102
Platelet count (Grade 3)200
Platelet Count (Grade 4)000
Leukocytes (Grade 3)100
Leukocytes (Grade 4)000
Lymphocytes (Grade 3)223
Lymphocytes (Grade 4)100
Aspartate Aminotransferase (Grade 3)200
Aspartate Aminotransferase (Grade 4)100
Alanine Aminotransferase (Grade 3)110
Alanine Aminotransferase (Grade 4)100
Bilirubin, Total (Grade 3)000
Bilirubin, TOTAL (Grade 4)100
Creatinine, (Grade 3)010
Creatinine (Grade 4)000
Potassium, (Grade 3)110
Potassium (Grade 4)000
Amylase (Grade 3)200
Amylase (Grade 4)000
Lipase (Grade 3)401
Lipase (Grade 4)000
Albumin, (Grade 3)100
Absolute Neutrophil Count (Grade 3)000
Absolute Neutrophil Count (Grade 4)000
Alkaline Phosphatase (Grade 3)000
Alkaline Phosphatase (Grade 4)000
Sodium (Grade 3)000
Sodium (Grade 4)000
Calcium, Total (Grade 3)000
Calcium, Total (Grade 4)000
Magnesium (Grade 3)000
Magnesium (Grade 4)000
Glucose (Grade 3)000
Glucose (Grade 4)000
Hypernatremia (Grade 3)000
Hypernatremia (Grade 4)000
Hyponatremia (Grade 3)000
Hyponatremia (Grade 4)000
Hyperkalemia (Grade 3)000
Hyperkalemia (Grade 4)000
Hypokalemia (Grade 3)110
Hypokalemia (Grade 4)000
Hypercalcemia (Grade 3)000
Hypercalcemia (Grade 4)000
Hypermagnesemia (Grade 3)000
Hypermagnesemia (Grade 4)000
Hypomagnesemia (Grade 3)000
Hypomagnesemia (Grade 4)000
Hypoglycemia (Grade 3)000
Hypoglycemia (Grade 4)000
PrimaryNumber of Participants With Laboratory Abnormalities in Specific Thyroid Tests

Blood samples were collected for specific thyroid test.

Time frame:
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsNIVO+IPI+TACENIVO+TACETACE
TSH > ULN (Upper Limit of Normal)555
TSH > ULN with TSH <= ULN at baseline543
TSH > ULN with at least one FT3/FT4 test value < LLN (Lower Limit of Normal)313
TSH > ULN with all other FT3/FT4 test values >= LLN544
TSH > ULN with FT3/FT4 test missing021
TSH < LLN310
TSH < LLN with TSH >= LLN at baseline310
TSH < LLN with at least one FT3/FT4 test value > ULN200
With all other FT3/FT4 test values <= ULN300
With FT3/FT4 test missing010
PrimaryNumber of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests

Blood samples were collected for specific liver tests.

Time frame:
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
ParticipantsNIVO+IPI+TACENIVO+TACETACE
ALT or AST > 5 X Upper limit of Normal (ULN)320
Alanine Transaminase (ALT) or AST > 10 X ULN210
ALT or Aspartate Transaminase (AST) > 20 X ULN100
Total Bilirubin > 2 X ULN321
ALP (Alkaline Phosphatase) > 1.5 X ULN555
Concurrent ALT OR AST Elevation > 3 X ULN with total Bilirubin > 2 X ULN within one day310
Concurrent ALT or AST elevation > 3 X ULN with total Bilirubin > 2 X ULN within 30 days320

Adverse events

Collected over All-cause mortality was collected from randomization until their study completion (up to approximately 38 months). Serious and non-serious adverse events were collected from first dose to 100 days after last dose of study therapy (up to approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NIVO+IPI+TACE2/9 (22.2%)7/9 (77.8%)9/9 (100%)
NIVO+TACE2/9 (22.2%)6/9 (66.7%)9/9 (100%)
TACE0/8 (0%)2/8 (25%)8/8 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventNIVO+IPI+TACENIVO+TACETACE
PyrexiaGeneral disorders1/93/90/8
Hepatic failureHepatobiliary disorders2/90/90/8
Hepatic encephalopathyNervous system disorders2/90/90/8
HaematemesisGastrointestinal disorders0/90/91/8
Klebsiella bacteraemiaInfections and infestations0/90/91/8
Abdominal pain upperGastrointestinal disorders0/91/90/8
DiarrhoeaGastrointestinal disorders1/90/90/8
Rectal haemorrhageGastrointestinal disorders0/91/90/8
Non-cardiac chest painGeneral disorders1/90/90/8
Hepatic infectionInfections and infestations1/90/90/8
Most frequent other events
Showing 10 of 138
Most frequent other events
EventNIVO+IPI+TACENIVO+TACETACE
ConstipationGastrointestinal disorders2/92/94/8
PruritusSkin and subcutaneous tissue disorders3/94/92/8
DiarrhoeaGastrointestinal disorders3/92/93/8
Oedema peripheralGeneral disorders1/91/93/8
Decreased appetiteMetabolism and nutrition disorders1/91/93/8
RashSkin and subcutaneous tissue disorders2/91/93/8
Abdominal painGastrointestinal disorders2/93/92/8
PyrexiaGeneral disorders2/93/92/8
AnaemiaBlood and lymphatic system disorders0/92/92/8
DyspepsiaGastrointestinal disorders0/91/92/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)NIVO+IPI+TACENIVO+TACETACETotal
Mean72.3 ± 10.2862.7 ± 11.1970.3 ± 8.8968.3 ± 10.70
Sex: Female, Male
Sex: Female, Male(Participants)NIVO+IPI+TACENIVO+TACETACETotal
Female2114
Male78722
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NIVO+IPI+TACENIVO+TACETACETotal
Hispanic or Latino0101
Not Hispanic or Latino0448
Unknown or Not Reported94417
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NIVO+IPI+TACENIVO+TACETACETotal
White3328
Black or African American0101
Asian0134
Chinese2215
Japanese2125
Not Reported2103
08

Study locations

107 sites
  • Local Institution - 0189
    Coronado, California 92118, United States
  • Local Institution
    Washington, District of Columbia 20007, United States
  • Local Institution - 0005
    Louisville, Kentucky 40202, United States
  • Local Institution - 0059
    Louisville, Kentucky 40217, United States
  • Local Institution - 0109
    Dallas, Texas 75203, United States
  • Local Institution
    Wollongong, New South Wales 2500, Australia
  • Local Institution - 0037
    Birtinya, Queensland 4575, Australia
  • Local Institution - 0010
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0001
    Melbourne, Victoria 3065, Australia
  • Local Institution - 0139
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0026
    Graz, 8036, Austria
  • Local Institution - 0013
    St. Polten, 3100, Austria
  • Local Institution
    Vienna, 1100, Austria
  • Local Institution - 0078
    West Springfield, 1090, Austria
  • Local Institution - 0048
    Wiener Neustadt, 2700, Austria
  • Local Institution - 0020
    Brussels, 1200, Belgium
  • Local Institution
    Federal District, 72115700, Belgium
  • Local Institution - 0053
    Gent, 9000, Belgium
  • Local Institution - 0050
    Plainfield, 1070, Belgium
  • Local Institution - 0039
    Quebec, G1R 2J6, Canada
  • Local Institution - 0184
    Beijing Shi, Beijing 100034, China
  • Local Institution
    Guangzhou, Guangdong 510060, China
  • Local Institution
    Guangzhou, Guangdong 510095, China
  • Local Institution
    Tianjin, Hebei 300060, China
  • Local Institution - 0196
    Nanjing Shi, Jiangsu 210009, China
  • Local Institution - 0176
    Nanchang, Jiangxi 330006, China
  • Local Institution
    Shenyang, Liaoning 110042, China
  • Local Institution - 0209
    Xi'an, Shan3xi 710100, China
  • Local Institution - 0151
    Shanghai, Shanghai 200040, China
  • Local Institution
    Chengdu, Sichuan 610041, China
  • Local Institution
    Hangzhou, Zhejiang 310003, China
  • Local Institution
    Hangzhou, Zhejiang 310022, China
  • Local Institution - 0055
    Olomouc, 779 00, Czechia
  • Local Institution
    Praha 5, 15000, Czechia
  • Local Institution - 0014
    Lille, Mount 59037, France
  • Local Institution - 0132
    Caen, 14033, France
  • Local Institution - 0021
    Clichy, 92110, France
  • Local Institution - 0064
    Dijon, 21000, France
  • Local Institution - 0082
    Englewood, 34295, France
  • Local Institution - 0052
    La Tronche, 38700, France
  • Local Institution - 0061
    Marseil, 13285, France
  • Local Institution - 0087
    Nantes, 44093, France
  • Local Institution - 0012
    Nice, 6202, France
  • Local Institution - 0093
    Paris, 75013, France
  • Local Institution - 0046
    Reims, 51092, France
  • Local Institution - 0094
    Villejuif cedex, 94805, France
  • Local Institution - 0035
    Goettingen, 37075, Germany
  • Local Institution
    Hannover, 30625, Germany
  • Local Institution
    Heidelberg, 69120, Germany
  • Local Institution - 0071
    Leipzig, 4103, Germany
  • Local Institution - 0045
    Hong Kong, 0, Hong Kong
  • Local Institution - 0004
    HongKong, 0, Hong Kong
  • Local Institution - 0015
    Orbassano, TO 10043, Italy
  • Local Institution
    Messina, 98124, Italy
  • Local Institution - 0025
    Milano, 20122, Italy
  • Local Institution
    Monserrato, 9042, Italy
  • Local Institution
    Parma, 43126, Italy
  • Local Institution
    Roma, 78584, Italy
  • Local Institution - 0076
    Siena, 53100, Italy
  • Local Institution - 0070
    Vicenza, 36100, Italy
  • Local Institution - 0108
    Chiba-shi, Chiba 260-8677, Japan
  • Local Institution - 0122
    Matsuyama-shi, Ehime 790-0024, Japan
  • Local Institution - 0148
    Sapporo-shi, Hokkaido 060-0033, Japan
  • Local Institution - 0118
    Kanazawa, Ishikawa 9208641, Japan
  • Local Institution - 0120
    Yokohama-shi, Kanagawa 2320024, Japan
  • Local Institution - 0113
    Yokohama-Shi, Kanagawa 241-0815, Japan
  • Local Institution - 0115
    Kyoto-Shi, Kyoto 602-0841, Japan
  • Local Institution - 0127
    Abeno-ku, Osaka 545-8586, Japan
  • Local Institution - 0125
    Izunokuni-Shi, Shizuoka 4102295, Japan
  • Local Institution - 0116
    Minato-ku, Tokyo 105-8470, Japan
  • Local Institution - 0128
    Minato-ku, Tokyo 105-8470, Japan
  • Local Institution - 0121
    Musashino-shi, Tokyo 180-8610, Japan
  • Local Institution - 0119
    Hiroshima, 734-8551, Japan
  • Local Institution - 0117
    Osaka, 589-8511, Japan
  • Local Institution - 0123
    Saitama, 350-0495, Japan
  • Local Institution - 0114
    Busan, 49241, Korea, Republic of
  • Local Institution - 0135
    Daegu, 41944, Korea, Republic of
  • Local Institution - 0047
    Gyeongsangnam-do, 050612, Korea, Republic of
  • Local Institution - 0097
    Hwasun-Gun, 58128, Korea, Republic of
  • Local Institution - 0161
    Seoul, 03080, Korea, Republic of
  • Local Institution - 0186
    Seoul, 05505, Korea, Republic of
  • Local Institution - 0160
    Seoul, 06351, Korea, Republic of
  • Local Institution - 0164
    Seoul, 120-752, Korea, Republic of
  • Local Institution
    Warszawa, 02-034, Poland
  • Local Institution - 0049
    San Juan, 00902, Puerto Rico
  • Local Institution - 0016
    Barnaul, 656049, Russian Federation
  • Local Institution - 0077
    Saint Petersburg, 197758, Russian Federation
  • Local Institution - 0009
    Saint-Petersburg, 198255, Russian Federation
  • Local Institution - 0027
    Singapore, 119074, Singapore
  • Local Institution - 0089
    Singapore, 217562, Singapore
  • Local Institution - 0011
    Singapore, 308433, Singapore
  • Local Institution - 0023
    Alicante, 03010, Spain
  • Local Institution - 0092
    Cordoba, 14004, Spain
  • Local Institution - 0101
    Madrid, 28007, Spain
  • Local Institution - 0183
    Madrid, 28027, Spain
  • Local Institution - 0084
    Madrid, 28034, Spain
  • Local Institution - 0018
    Madrid, 28041, Spain
  • Local Institution - 0099
    Pamplona, 31008, Spain
  • Local Institution - 0131
    Sabadell, 8208, Spain
  • Local Institution - 0102
    Santiago de Compostela, 15706, Spain

Showing the first 100 of 107 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2023, 38 months.

Results were first posted in Nov 2024, 11 months after primary completion.

Of 30 phase 3 interventional studies under Liver Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 97. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2020
First posted
Apr 9, 2020
StartActual
Sep 14, 2020
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Results first posted
Nov 26, 2024
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04340193
Responsible party
Sponsor
First posted
Apr 9, 2020
Start date
Sep 14, 2020
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Results posted
Nov 26, 2024
Last update
Nov 26, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion